Profusa (NASDAQ: PFSA) has announced the launch of its healthcare research version of its Lumee tissue oxygen monitoring into the contract research organizations (CRO) market, which is expected to generate immediate service-based revenue.
According to Profusa, the company is building on its established success with its Lumee oxygen tissue-integrated biosensor technologies. It will now offer the Lumee tissue oxygen system as commercial research-use-only kits and a service-enabled platform for CRO partners. This provides researchers and R&D teams access to continuous, real-time measurement of tissue oxygenation, providing critical insights across a range of applications including advanced in vitro and organ-on-chip models, preclinical pharmacology and toxicology studies, and translational research programs.
The company has appointed Sean Givens as head of government and healthcare research business, who commented, “This is a natural and timely extension of Profusa’s platform building off of previous successes of this market. Our sensors are validated, ready to ship, and already generating strong interest across the industry. By partnering with CROs, we can help accelerate better drug development decisions while creating a meaningful, near-term revenue stream for Profusa.”
